GPN Vaccines

Developing a serotype-independent vaccine against Streptococcus pneumoniae, the world's foremost bacterial pathogen
GPN Vaccines
Operating

GPN Vaccines is a public (unlisted) biotechnology company developing a vaccine against Streptococcus pneumoniae, the bacteria responsible for causing life-threatening pneumonia, bacteraemia and meningitis, as well as otitis media (middle ear infections). Each year it causes 1-2 million deaths worldwide, killing more children than AIDS, malaria and tuberculosis combined. There are now 100 different strains of S. pneumoniae, however the best vaccine currently on the market only protects against 13 strains. Our vaccine, Gamma-PN, is being developed to protect children and adults against all strains of S. pneumoniae.

Investors
Investor

Southern Angels

Images
Taken on 2021-02
 Location
Adelaide
 People
 Tags
#biomedicine
#biotech
 Feedback